First Test of Anti-Cancer Agent PAC-1 (Procaspase -Activating Compound-1) in Human Clinical Trials Shows Promise

Arkadiusz Dudek, MD
A phase I clinical trial of PAC-1, a drug that spurs programmed cell death in cancer cells, found only minor side effects in patients with end-stage cancers. The drug stalled the growth of tumors in the five people in the trial with neuroendocrine cancers and reduced tumor size in two of those patients. It also showed some therapeutic activity against sarcomas, scientists and clinicians reported on December 5, 2022 in the British Journal of Cancer. The article is titledPhase I Study of Procaspase-Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies.” The drug was first identified and developed as an anti-cancer agent by scientists at the University of Illinois Urbana-Champaign.
Login Or Register To Read Full Story